Cardiogen Injectable
Cardiogen 20 mg contains the AED tripeptide (Ala-Glu-Asp), a synthetic bioregulator developed by Russian scientist Vladimir Khavinson for cardiac tissue research. It belongs to the Khavinson short peptide class, which is investigated for proposed epigenetic mechanisms involving direct interaction with DNA and modulation of gene expression in target tissues.
In research contexts, Cardiogen is studied for its potential effects on cardiomyocyte gene expression, including regulation of contractile proteins and anti-apoptotic pathways. Preclinical studies have investigated its effects on cardiac antioxidant enzyme activity, fibrosis markers, and cardiomyocyte proliferation following ischemic injury. The proposed mechanism involves sequence-specific DNA binding, with Cardiogen showing affinity for specific gene promoter regions.
In bodybuilding and cardiovascular health contexts, Cardiogen is referenced anecdotally for supporting cardiac function and recovery from cardiovascular stress. However, all published research originates from a single Russian research program, and no Western clinical trials or independent replications have been conducted. Such use falls outside any approved indication, and Cardiogen has no FDA-approved human product.
Research Properties of Cardiogen 20 mg
- AED tripeptide sequence (Ala-Glu-Asp)
- Proposed epigenetic modulation of cardiomyocyte gene expression
- Investigated for anti-fibrotic and antioxidant effects in cardiac tissue
- Lyophilized powder format for extended stability
- 20 mg per vial for research applications
AED Tripeptide Bioregulator
Cardiogen belongs to the Khavinson bioregulator class, a family of ultrashort peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology for proposed tissue-specific regulatory effects. The AED sequence (Ala-Glu-Asp) is specifically associated with cardiac tissue in this research framework.
The proposed mechanism involves direct interaction with DNA and core histones after cellular penetration. Khavinson peptides are thought to bind to specific promoter regions, modulating chromatin accessibility and enabling transcription of genes associated with tissue homeostasis. Cardiogen has demonstrated binding to gene promoter regions in cardiac tissue cultures in Russian studies.
Research has investigated Cardiogen's effects on cardiac gene expression, including upregulation of genes associated with contractile proteins and antioxidant enzymes. Animal models have reported reduced collagen deposition and fibrotic markers in aged rat hearts following Cardiogen treatment.
Defining Characteristic
Epigenetic Mechanism of Action
Cardiogen is proposed to act through direct DNA interaction and gene expression modulation rather than cell-surface receptor binding. This epigenetic mechanism differs fundamentally from conventional cardiovascular medications (beta-blockers, ACE inhibitors, statins).
Cardiogen 20 mg vs Other Dragon Pharma Preparations
Dragon Pharma offers several Khavinson bioregulators and research peptides with different tissue targets. Bronchogen is the AEDL tetrapeptide targeting bronchial epithelium, while Vesugen is the KED tripeptide for vascular endothelium. Testagen is the KEDG tetrapeptide investigated for endocrine regulation. These compounds share the Khavinson epigenetic paradigm but differ in their proposed tissue targets and amino acid sequences.
Typical Dosage Ranges
Common reference ranges for Cardiogen are derived primarily from Russian bioregulator protocols and community practices rather than controlled clinical trials. The standard pattern involves short cycles of 10–30 days with daily administration, followed by extended rest periods. Community sources reference injectable doses of 500–1000 mcg daily, while oral capsule protocols use higher milligram amounts due to lower bioavailability.
| Use Case |
Common Reference Range |
Frequency |
| Standard research cycle |
500–1000 mcg |
Daily for 20–30 days |
| Oral capsule protocol |
10–20 mg |
Daily for 10–20 days |
| Maintenance/longevity |
300–500 mcg |
20 days per quarter |
Reconstitution & Handling
Cardiogen 20 mg is supplied as a lyophilized powder requiring reconstitution. Bacteriostatic Water is commonly referenced for reconstituting research peptides. A 20 mg vial reconstituted with 2 mL yields a concentration of 10 mg/mL. Standard sterile technique and peptide handling practices should be observed.
Stacking & Research Considerations
In Khavinson bioregulator protocols, Cardiogen is sometimes referenced alongside other tissue-specific peptides. Bronchogen (bronchial tissue) and Vesugen (vascular endothelium) are the most commonly mentioned companions in cardiovascular-respiratory research contexts. However, no controlled studies have examined the safety or efficacy of these combinations.
Important
Individual Response Varies
The information above is for educational reference and does not constitute medical advice. Cardiogen has not been evaluated by the FDA for safety or efficacy.
Important Safety Information
No formal safety data exists for Cardiogen. All published research originates from a single Russian research program, and no independent Western replication or controlled human trials have been conducted. Pharmacokinetics, bioavailability, and optimal dosing in humans are completely uncharacterized.
Important
Non-Medical Use
Non-medical use of Cardiogen falls outside any approved indication. Product purity does not establish that non-medical use is safe or appropriate for an individual.
Potential Adverse Effects
Because Cardiogen is proposed to interact with DNA and modulate gene expression, theoretical risks include unintended effects on cellular regulation. No systematic human safety data are available to characterize common or rare adverse effects. Russian trials report generally good tolerability with rare mild side effects, but this is anecdotal and not derived from controlled trials.
Conditions Requiring Medical Evaluation
Individuals with active cardiac conditions, known hypersensitivity to peptide products, or pregnancy/breastfeeding status should exercise particular caution. No formal contraindication list exists for Cardiogen because it has not undergone Western regulatory review.
Monitoring Considerations
If Cardiogen is used in any research context, monitoring of cardiac function may be considered, though no standardized protocol exists. Laboratory testing of the product itself is separate from clinical monitoring of the individual.
Product Care
Storage & Handling
Store the lyophilized powder at -20°C for long-term storage, protected from light and moisture. Reconstitute only immediately before use and store at 2–8°C. Do not freeze reconstituted solution.
Keep all research peptides and injectable products out of the reach of children.
USA Domestic 3–5 business days
International 10–15 business days
Order Processing 24–48 business hours
Tracking Provided after dispatch
Direct Supply
Discreet Delivery & Original Packaging
The outer shipping package remains discreet, with no external product details. Products are supplied through the official Dragon Pharma distribution chain.
What to Expect
- Orders are processed after payment confirmation
- USA Domestic shipping is typically faster when local stock is available
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity Verification
To verify your Cardiogen 20 mg product, use the security code on the vial label and cross-check it on the official Dragon Pharma site. Original packaging and batch documentation help reinforce product legitimacy.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Recommended Conditions
Store the lyophilized powder at -20°C for long-term storage, protected from light and moisture. The unopened vial should be kept under conditions that preserve the peptide's structural integrity until reconstitution.
Once reconstituted, Cardiogen solution should be stored at 2–8°C and used within a reasonable timeframe. Do not freeze reconstituted solution. Discard if solution becomes cloudy or develops particulate matter.
Keep out of reach of children. Follow proper handling practices for research peptides and use appropriate sterile technique during reconstitution.
Quick Reference
Do & Don't
- Do store lyophilized powder at -20°C for long-term storage
- Do protect from light and moisture
- Do store reconstituted solution at 2–8°C
- Don't freeze reconstituted solution
- Don't expose to excessive heat
- Don't use if powder appears discolored
What is Cardiogen 20 mg used for?
Cardiogen 20 mg is a research peptide supplied as a lyophilized powder. It contains the AED tripeptide, which is investigated for proposed epigenetic effects on cardiomyocyte gene expression. There is no FDA-approved human indication for Cardiogen.
How often should Cardiogen 20 mg be administered?
Common reference ranges for Cardiogen are derived from Russian bioregulator protocols rather than controlled trials. Standard patterns involve 500–1000 mcg daily for 20–30 days, followed by extended rest periods.
Does Cardiogen 20 mg require PCT?
Cardiogen is not an anabolic steroid and does not suppress endogenous testosterone production. Post-cycle therapy designed for steroid cycles is not applicable. Its proposed epigenetic mechanism is distinct from hormonal suppression.
What does Cardiogen do?
Cardiogen is proposed to penetrate cell nuclei and interact with DNA to modulate gene expression in cardiac tissues. Research has investigated its effects on contractile protein genes and anti-apoptotic pathways. These mechanisms remain investigational and have not been independently validated.
How long does Cardiogen take to work?
No established onset timeline exists for Cardiogen in humans because no controlled trials have been completed. Its proposed epigenetic mechanism would theoretically involve gene expression changes that develop over days to weeks, with effects persisting after the peptide clears.
Is Cardiogen the best cardiac peptide?
No single cardiac peptide is universally superior. The Khavinson peptide class includes multiple compounds investigated for different tissue targets. Cardiogen's research focus on cardiac tissue is distinct from other peptides in Dragon Pharma's catalog.
What is the difference between Cardiogen and Bronchogen?
Cardiogen (AED) and Bronchogen (AEDL) are both Khavinson bioregulators but have different amino acid sequences and proposed tissue targets. Cardiogen is associated with cardiac tissue, while Bronchogen targets bronchial epithelium.
What is the difference between Cardiogen and Vesugen?
Cardiogen (AED) and Vesugen (KED) are both Khavinson bioregulators but differ in sequence and proposed targets. Cardiogen targets cardiac tissue, while Vesugen targets vascular endothelium.
Is 20 mg of Cardiogen a lot?
20 mg is the total labeled content of the Cardiogen 20 mg vial. Because no standardized human dosage exists for this research peptide, the milligram amount cannot be classified as high or low relative to established protocols. Community protocols reference doses in the microgram range for injectable use.
What strength is Cardiogen 20 mg?
Cardiogen 20 mg by Dragon Pharma contains 20 mg of Cardiogen per vial as a lyophilized powder. The vial size is 2 mL. This is a research presentation.
Can Cardiogen be stacked with other peptides?
In Khavinson bioregulator protocols, Cardiogen is sometimes referenced alongside other tissue-specific peptides. Bronchogen and Vesugen are the most commonly mentioned companions. However, no controlled studies have examined the safety or efficacy of these combinations.
No reviews found
Please log in to write Cardiogen 20 mg review.
